Editas Medicine, Inc.

Editas Medicine, Inc.

EDIT
Editas Medicine, Inc.US flagNASDAQ Global Select
1.35
USD
+0.03
(+2.27%)
-2.88EPS
-0.47P/E
113.01MMarket Cap
May 06Next Earn
Capital Structure

in mil. unless spec.
Working Capital

in mil. unless spec.
Growth Rates

in mil. unless spec.
Quarterly Revenue

in mil. unless spec.
Quarterly Earnings Per Share

in mil. unless spec.
Quarterly Dividends Per Share

in mil. unless spec.

Company Description

CEO
Dr. Gilmore O'Neill M.D.
Full Time Employees
246
Sector
Healthcare
Industry
Biotechnology
Address
11 Hurley Street Cambridge MA United States of America 02141
IPO Date
Feb 3, 2016
Similar Companies
Business
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Company News

  • Why Is Editas (EDIT) Down 37.1% Since Last Earnings Report?

  • Editas Medicine Announces Chief Financial Officer Transition

  • Editas Medicine, Inc. (EDIT) Barclays 27th Annual Global Healthcare Conference (Transcript)

  • Editas Medicine, Inc. (EDIT) Leerink Partners Global Healthcare Conference (Transcript)

  • Editas Q4 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down

  • Editas Medicine (EDIT) Reports Q4 Loss, Misses Revenue Estimates

  • Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates

  • Editas Medicine, Inc. (EDIT) TD Cowen 45th Annual Health Care Conference Transcript

  • Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March

  • Editas And Intellia: Strategic Shifts And Long-Term Investment Potential

  • Editas Medicine, Inc. (EDIT) 43rd Annual JPMorgan Healthcare Conference - (Transcript)

  • Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities

  • Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference

  • EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut Workforce

  • Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026

  • Editas to reduce about 65% of its workforce over the next six months

  • Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years

  • Editas Stock Rises on Updated Data From SCD Study of Reni-Cel

  • Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting

  • Why Is Editas (EDIT) Down 36.5% Since Last Earnings Report?